Detalhe da pesquisa
1.
Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change.
J BUON
; 21(6): 1379-1382, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28039695
2.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 16(7): 763-74, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26045340
3.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
4.
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability.
BMC Proc
; 18(Suppl 3): 2, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233854
5.
An international survey of practice patterns and difficulties in cancer pain management in Southeastern Europe: a Turkish & Balkan Oncology Group common initiative.
J BUON
; 18(4): 1082-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24344043
6.
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 13(3): 247-55, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22341744
7.
The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.
Curr Oncol
; 30(8): 7218-7228, 2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37623004
8.
Perspectives for Cancer Care and Research in Central and Eastern Europe.
Oncol Res Treat
; 46(3): 80-88, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463856
9.
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
Curr Oncol
; 29(8): 5833-5845, 2022 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36005198
10.
A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.
Breast Care (Basel)
; 15(1): 67-71, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32231500
11.
The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Lung Cancer
; 63(2): 271-6, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18565617
12.
Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med
; 353(2): 123-32, 2005 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-16014882
13.
ESMO 2017-my personal highlights.
Memo
; 11(1): 77-79, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29606982
14.
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
J BUON
; 12 Suppl 1: S137-49, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17935272
15.
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Lung Cancer
; 105: 1-6, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28236978
16.
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
J Thorac Oncol
; 11(6): 808-18, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26980471
17.
Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
Lung Cancer
; 47(1): 93-101, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15603859
18.
Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].
Breast Care (Basel)
; 15(3): 314-316, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32774227
19.
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Clin Lung Cancer
; 15(3): 188-196.e2, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24560012
20.
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 15(6): 418-25, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25104617